Articles by tag: asco-2026

Reqorsa Gene Therapy: Analysis of ASCO-2026 Data and Prospects

Critical analysis of Reqorsa gene therapy results at ASCO-2026: sample of 18 patients, p=0.05, risks for investors and the real situation of Genprex. Read details.

Oncolytics Biotech immunotherapy for pancreatic cancer ASCO 2026

Oncolytics Biotech data at ASCO 2026: pelareorep virus activates T cells against mutant KRAS in pancreatic cancer. Learn about the breakthrough in treating 'cold' tumors.